NATCO Pharma Past Earnings Performance
Past criteria checks 6/6
NATCO Pharma has been growing earnings at an average annual rate of 26%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 16.7% per year. NATCO Pharma's return on equity is 28%, and it has net margins of 37.6%.
Key information
26.0%
Earnings growth rate
26.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 16.7% |
| Return on equity | 28.0% |
| Net Margin | 37.6% |
| Next Earnings Update | 12 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How NATCO Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 43,490 | 16,365 | 5,288 | 0 |
| 31 Mar 24 | 40,020 | 13,883 | 5,360 | 0 |
| 31 Dec 23 | 38,298 | 12,778 | 5,537 | 0 |
| 30 Sep 23 | 35,637 | 11,274 | 5,665 | 0 |
| 30 Jun 23 | 29,630 | 8,152 | 4,730 | 0 |
| 31 Mar 23 | 27,085 | 7,153 | 4,733 | 0 |
| 31 Dec 22 | 24,074 | 3,890 | 5,037 | 0 |
| 30 Sep 22 | 24,754 | 4,071 | 5,163 | 0 |
| 30 Jun 22 | 24,191 | 4,154 | 4,595 | 0 |
| 31 Mar 22 | 19,462 | 1,700 | 5,005 | 0 |
| 31 Dec 21 | 16,833 | 2,735 | 4,659 | 0 |
| 30 Sep 21 | 14,780 | 2,558 | 4,491 | 0 |
| 30 Jun 21 | 18,990 | 3,931 | 4,278 | 0 |
| 31 Mar 21 | 20,561 | 4,409 | 4,507 | 0 |
| 31 Dec 20 | 21,756 | 4,820 | 5,043 | 0 |
| 30 Sep 20 | 23,026 | 5,238 | 5,007 | 0 |
| 30 Jun 20 | 19,861 | 4,404 | 3,770 | 0 |
| 31 Mar 20 | 19,150 | 4,608 | 4,774 | 0 |
| 31 Dec 19 | 19,159 | 4,875 | 3,807 | 0 |
| 30 Sep 19 | 19,904 | 5,425 | 3,762 | 0 |
| 30 Jun 19 | 20,482 | 6,060 | 3,664 | 0 |
| 31 Mar 19 | 20,945 | 6,444 | 4,466 | 0 |
| 31 Dec 18 | 24,066 | 8,235 | 4,008 | 0 |
| 30 Sep 18 | 24,121 | 8,815 | 3,863 | 0 |
| 30 Jun 18 | 22,953 | 7,838 | 3,512 | 0 |
| 31 Mar 18 | 21,848 | 6,962 | 3,422 | 0 |
| 31 Dec 17 | 19,817 | 5,730 | 3,124 | 0 |
| 30 Sep 17 | 20,895 | 5,506 | 2,975 | 0 |
| 30 Jun 17 | 21,679 | 5,323 | 2,546 | 0 |
| 31 Mar 17 | 20,202 | 4,860 | 2,698 | 0 |
| 31 Dec 16 | 17,697 | 3,680 | 2,071 | 0 |
| 30 Sep 16 | 13,692 | 2,113 | 2,187 | 0 |
| 30 Jun 16 | 12,431 | 1,748 | 1,960 | 0 |
| 31 Mar 16 | 10,423 | 1,549 | 1,918 | 0 |
| 31 Dec 15 | 9,355 | 1,494 | 2,569 | 126 |
| 30 Sep 15 | 8,549 | 1,266 | 2,432 | 126 |
| 30 Jun 15 | 8,390 | 1,294 | 1,454 | 0 |
| 31 Mar 15 | 7,305 | 1,293 | 1,276 | 0 |
| 31 Dec 14 | 8,089 | 1,042 | 2,013 | 143 |
| 30 Sep 14 | 8,108 | 1,199 | 1,977 | 143 |
| 30 Jun 14 | 7,648 | 1,144 | 1,187 | 0 |
| 31 Mar 14 | 7,389 | 1,027 | 1,847 | 143 |
| 31 Dec 13 | 7,078 | 900 | 1,520 | 146 |
Quality Earnings: 524816 has high quality earnings.
Growing Profit Margin: 524816's current net profit margins (37.6%) are higher than last year (27.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524816's earnings have grown significantly by 26% per year over the past 5 years.
Accelerating Growth: 524816's earnings growth over the past year (100.7%) exceeds its 5-year average (26% per year).
Earnings vs Industry: 524816 earnings growth over the past year (100.7%) exceeded the Pharmaceuticals industry 19.1%.
Return on Equity
High ROE: 524816's Return on Equity (28%) is considered high.